Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.54 |
| ▸ | CA2 | P00918 | 4/20 | 0.54 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA7 | P43166 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13779473 | 0.98 | CA1 (0.50) | CA1CA2CA12CA7CA9 | |
| SCHEMBL29141387 | 0.88 | LMNA (0.47) | LMNAGAAKDM4ETSHRMAPT | |
| SCHEMBL14344872 | 0.85 | CYP1A2 (0.59) | CA1CA2CA12CA7CA9 | |
| SCHEMBL23796581 | 0.82 | CYP3A4 (0.56) | CA1CA2CA12CA7CA9 | |
| SCHEMBL8395371 | 0.82 | GAA (0.45) | CA1CA2CA12CA7CA9 | |
| SCHEMBL399550 | 0.81 | KDM4E (0.57) | CA1CA2CA12CA7CA9 | |
| SCHEMBL3308973 | 0.79 | BCL2L1 (0.47) | CA1CA2CA12CA7CA9 | |
| SCHEMBL3310733 | 0.79 | KDR (0.43) | CA1CA2CA12CA7CA9 | |
| SCHEMBL11253706 | 0.79 | GAA (0.51) | CA1CA2CA12CA7CA9 | |
| SCHEMBL23302512 | 0.79 | CA12 (0.42) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200331828-A1 | NOVEL COMPOUNDS WHICH ACTIVATE ESTROGEN RECEPTORS AND COMPOSITIONS AND METHODS OF USING THE SAME | UNIV ILLINOIS (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200331828-A1 | NOVEL COMPOUNDS WHICH ACTIVATE ESTROGEN RECEPTORS AND COMPOSITIONS AND METHODS OF USING THE SAME | UNIV ILLINOIS (US) | 2020-10-22 | — | — | US | disclosed |
| US-10703698-B2 | Compounds which activate estrogen receptors and compositions and methods of using the same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2020-07-07 | — | — | US | disclosed |
| US-10703698-B2 | Compounds which activate estrogen receptors and compositions and methods of using the same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190002380-A1 | NOVEL COMPOUNDS WHICH ACTIVATE ESTROGEN RECEPTORS AND COMPOSITIONS AND METHODS OF USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2019-01-03 | — | — | US | disclosed |
| US-20190002380-A1 | NOVEL COMPOUNDS WHICH ACTIVATE ESTROGEN RECEPTORS AND COMPOSITIONS AND METHODS OF USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2019-01-03 | — | — | US | disclosed |
| EP-3400071-A1 | NOVEL COMPOUNDS WHICH ACTIVATE ESTROGEN RECEPTORS AND COMPOSITIONS AND METHODS OF USING THE SAME | The Board of Trustees of the University of Illinois (US) | 2018-11-14 | — | — | EP | disclosed |
| WO-2017120507-A1 | NOVEL COMPOUNDS WHICH ACTIVATE ESTROGEN RECEPTORS AND COMPOSITIONS AND METHODS OF USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-07-13 | — | — | WO | disclosed |
| WO-2017120507-A1 | NOVEL COMPOUNDS WHICH ACTIVATE ESTROGEN RECEPTORS AND COMPOSITIONS AND METHODS OF USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10703698-B2 | Compounds which activate estrogen receptors and compositions and methods of using the same | GPER1, ESRRG, ESR2 | CA1 618/4885CA2 2016/4885CA12 1928/4885 |
| US-20190002380-A1 | NOVEL COMPOUNDS WHICH ACTIVATE ESTROGEN RECEPTORS AND COMPOSITIONS AND METHODS OF USING THE SAME | GPER1, ESRRG, ESR2 | CA1 810/4885CA2 2607/4885CA12 1930/4885 |
| US-20200331828-A1 | NOVEL COMPOUNDS WHICH ACTIVATE ESTROGEN RECEPTORS AND COMPOSITIONS AND METHODS OF USING THE SAME | GPER1, ESRRG, ESR2 | CA1 810/4885CA2 2607/4885CA12 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.